PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 171 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $258,689 | -75.3% | 9,366 | -79.4% | 0.00% | -80.0% |
| Q1 2023 | $1,045,879 | +24.5% | 45,473 | -40.9% | 0.01% | +25.0% |
| Q4 2022 | $839,961 | +29.4% | 76,990 | 0.0% | 0.00% | +33.3% |
| Q3 2022 | $649,000 | +15.7% | 76,990 | +8.5% | 0.00% | 0.0% |
| Q2 2022 | $561,000 | -54.3% | 70,930 | +49.7% | 0.00% | -50.0% |
| Q1 2021 | $1,227,000 | +26.8% | 47,387 | -1.3% | 0.01% | +50.0% |
| Q4 2020 | $968,000 | +6.0% | 48,007 | +2.8% | 0.00% | 0.0% |
| Q3 2020 | $913,000 | +10.7% | 46,707 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $825,000 | +300.5% | 46,707 | +60.4% | 0.00% | +300.0% |
| Q1 2020 | $206,000 | – | 29,117 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |